CD83 Antibody (HB15e) [Alexa Fluor™ Plus 647]

• Clone: HB15e
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 647

CD83 Antibody (HB15e) [Alexa Fluor™ Plus 647] Summary

• Immunogen: COS-7 African green monkey SV40 transformed kidney fibroblast-like cells transfected with human CD83
• Specificity: Detects human CD83.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Human CD83 is a 40‑50 kDa member of the Siglec (or sialic-acid-binding immunoglobulin-like lectin) family of transmembrane proteins (1, 2, 3). CD83 is synthesized as a type I transmembrane glycoprotein that contains a 125 amino acid (aa) extracellular region, a 22 aa transmembrane segment, and 39 aa cytoplasmic domain. It contains one V type Ig-like domain in the extracellular region with no inhibitory cytoplasmic motif(s). Although in vitro studies suggest CD83 may form membrane-bound covalent homodimers, in vivo this does not appear to be the case (1, 4). In the extracellular region, mouse and human CD83 are 66% aa identical (1, 2, 4, 5). Relative to human, mouse CD83 is 11 aa shorter in its extracellular domain and is expressed as a 30‑35 kDa protein (1, 4, 5). Human CD83 is active in the mouse system (4). One alternate splice form has been reported. This leads to a small monomeric soluble form of 74 aa that includes aa 20‑52 and aa 164‑205 (6, 7). In human, proteolytic cleavage and solubilization of CD83 has also been suggested, and this could lead to dimeric circulating CD83 (4, 6). CD83 is a primary marker for dendritic cells (3, 6, 8). It is also found on B cells (6, 9), neutrophils (10), monocytes and macrophages (11). Except for dendritic cells, CD83 expression is often transient. CD83 binds to sialic acids on target cells (12). Membrane CD83 appears to promote T cell proliferation, particularly of CD8⁺ cytotoxic T cells (13, 14). Soluble CD83, however, appears to be immunosuppressive and blocks T cell activation (15, 16). On monocytes, CD83 is suggested to drive monocytes into a fibrocyte phenotype (13). A lack of membrane-expressed CD83 leads to an unusual IL-4/IL-10 producing CD4⁺ T cell phenotype (17).

1. Zhou, L-J. et al. (1992) J. Immunol. 149:735.
2. Kozlow, E.J. et al. (1993) Blood 81:454.
3. Fujimoto, Y and T.F. Tedder (2006) J. Med. Dent. Sci. 53:85.
4. Lechmann, M. et al. (2005) Biochem. Biophys. Res. Commun. 329:132.
5. Berchtold, S. et. al. (1999) FEBS Lett. 461:211.
6. Hock, B.D. et al. (2001) Int. Immunol. 13:959.
7. Dudziak, D. et al. (2005) J. Immunol. 174:6672.
8. Velten, F.W. et al. (2007) Mol. Immunol. 44:1544.
9. Cramer, S.O. et al. (2000) Int. Immunol. 12:1347.
10. Yamashiro, S. et al. (2000) Blood 96:3958.
11. Cao, W. et al. (2005) Biochem. J. 385:85.
12. Scholler, N. et al. (2001) J. Immunol. 166:3865.
13. Scholler, N. et al. (2002) J. Immunol. 168:2599.
14. Hirano, N. et al. (2006) Blood 107:1528.
15. Kotzor, N. et al. (2004) Immunobiology 209:129.
16. Zinser, E. et al. (2006) Immunobiology 211:449.
17. Garcia-Martinez, L.F. et al. (2004) J. Immunol. 173:2995.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.